FDA Sets Clock for SYMVESS Patent Extension Review
Published Date: 2/19/2026
Notice
Summary
The FDA has set the official review period for SYMVESS, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind SYMVESS and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until April 20 or August 18, 2026, to speak up—potentially impacting patent length and market exclusivity.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA sets SYMVESS review period
If you are the patent holder (Humacyte Global, Inc.), FDA has determined the regulatory review period for SYMVESS is 3,069 days total: 2,694 days in the testing phase and 375 days in the approval phase. FDA lists the key dates as an IND effective July 27, 2016, a BLA submission on December 11, 2023, and approval on December 19, 2024; the applicant requests 1,572 days of patent term extension and the FDA determination establishes the product's maximum potential extension length before USPTO applies statutory limits.
Deadlines to challenge SYMVESS dates
Anyone who thinks the dates are wrong may ask FDA for a redetermination by April 20, 2026, and anyone may petition FDA about whether the applicant acted with due diligence by August 18, 2026. Petitions must follow FDA rules (21 CFR 60.24 and 21 CFR 60.30) and be filed electronically or by written submission as described in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16728, Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16727, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of this device type.
Previous / Next Documents
Previous: 2026-03311, Agency Information Collection Activities; Proposed Collection; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA wants your thoughts on how they collect info about safely processing and importing fish and seafood. This affects businesses that handle fish products, aiming to keep seafood safe and clean. You’ve got until April 20, 2026, to share your comments—no fees, just your voice helping shape safer seafood rules!
Next: 2026-03313, Agency Information Collection Request. 60-Day Public Comment Request
The Department of Health and Human Services’ Office of Minority Health wants your thoughts on keeping their Think Cultural Health info collection going—no changes, just a renewal. This helps health pros sign up for courses and earn credits to better serve diverse communities. You’ve got until April 21, 2026, to share your comments, and there’s no new cost involved.